Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7571476 | 0.90 | KCNH2 (0.52) | KCNH2HSD17B10USP2PAK1CYP1A2 | |
| SCHEMBL7595465 | 0.86 | ALOX5 (0.54) | KCNH2HSD17B10USP2PAK1CYP1A2 | |
| SCHEMBL4885527 | 0.84 | IDO1 (0.54) | KCNH2HSD17B10USP2PAK1CYP1A2 | |
| SCHEMBL11196561 | 0.81 | HTR1B (0.56) | KCNH2HSD17B10USP2PAK1CYP1A2 | |
| SCHEMBL2703781 | 0.81 | GAA (0.53) | KCNH2CYP2C9CNR1CNR2TDP1 | |
| SCHEMBL9870108 | 0.81 | TSHR (0.47) | HSD17B10CYP1A2CYP2C19SLC2A1CNR1 | |
| Ammonia Solution, Strong SCHEMBL27937782 | 0.79 | TSHR (0.46) | HSD17B10CYP1A2CYP2C19SLC2A1CNR1 | |
| SCHEMBL29371827 | 0.78 | TLR8 (0.44) | CYP1A2SLC2A1CNR1CNR2TDP1 | |
| SCHEMBL7966951 | 0.78 | TLR8 (0.44) | CYP1A2SLC2A1CNR1CNR2TDP1 | |
| SCHEMBL15345502 | 0.77 | SLC2A1 (0.49) | SLC2A1CNR1CNR2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448864-A2 | SILICA-BASED PARTICLE COMPOSITION | Nalco Company (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011028497-A2 | CALCIUM-BASED CARRIER PARTICLES | NALCO COMPANY (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028496-A2 | CALCIUM BASED CARRIER PARTICLES | NALCO COMPANY (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028498-A2 | CALCIUM-BASED CARRIER PARTICLES | NALCO COMPANY (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028469-A2 | CALCIUM BASED CARRIER PARTICLES | NALCO COMPANY (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110046241-A1 | CALCIUM BASED CARRIER PARTICLES | NANOSPECIALTIES, LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046240-A1 | CALCIUM-BASED CARRIER PARTICLES | NALCO COMPANY | 2011-02-24 | — | — | US | disclosed |
| US-20110046239-A1 | CALCIUM BASED CARRIER PARTICLES | NANOSPECIALTIES, LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046238-A1 | CALCIUM BASED CARRIER PARTICLES | NANOSPECIALTIES, LLC | 2011-02-24 | — | — | US | disclosed |
| WO-2011008492-A2 | SILICA-BASED PARTICLE COMPOSITION | NALCO COMPANY (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008484-A2 | SILICA-BASED PARTICLE COMPOSITION | NALCO COMPANY (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20100330366-A1 | SILICA-BASED PARTICLE COMPOSITION | NANOSPECIALTIES, LLC | 2010-12-30 | — | — | US | disclosed |
| US-20100331431-A1 | SILICA-BASED PARTICLE COMPOSITION | NALCO COMPANY | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046241-A1 | CALCIUM BASED CARRIER PARTICLES | ORAI1, CA7, ACP1 | KCNH2 644/4885HSD17B10 2328/4885USP2 3559/4885 |
| US-20110046240-A1 | CALCIUM-BASED CARRIER PARTICLES | ORAI1, CA7, CA4 | KCNH2 669/4885HSD17B10 2143/4885USP2 3438/4885 |
| US-20110046238-A1 | CALCIUM BASED CARRIER PARTICLES | ORAI1, CA7, ACP1 | KCNH2 644/4885HSD17B10 2328/4885USP2 3559/4885 |
| US-20110046239-A1 | CALCIUM BASED CARRIER PARTICLES | ORAI1, CA7, ACP1 | KCNH2 644/4885HSD17B10 2328/4885USP2 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.